| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3944537 | Gynecologic Oncology | 2008 | 5 Pages |
Abstract
The role of neoadjuvant chemotherapy (NACT) in cervical cancer has been a matter of investigation over the last 20 years. A systematic review and meta-analysis of individual patient data (IPD) demonstrated that NACT followed by surgery is superior to radiotherapy alone in terms of overall survival. However, in spite of the results of the meta-analysis, NACT has not been adopted as the new standard of care. In the present paper, we review the reasons why NACT is still considered an investigational approach in cervical cancer.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Antonio González-Martín, Lucía González-Cortijo, Natalia Carballo, Juan F. Garcia, Fernando Lapuente, Alejandro Rojo, Luis M. Chiva,